Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06663358 · ClinicalTrials.gov registry record

A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients

A clinical trial of Fabry Disease, sponsored by Chiesi Farmaceutici S.p.A..

Recruiting
Registry status
100
Enrollment target
10
Study locations

NCT06663358 is a study of Fabry Disease that is actively recruiting participants, run by Chiesi Farmaceutici S.p.A.. The registered enrollment target is 100 participants, below the 540-participant average among 32 other Fabry Disease trials with a reported enrollment target (81% lower). The trial reports 10 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06663358, a study of Fabry Disease, is actively recruiting participants, sponsored by Chiesi Farmaceutici S.p.A..

RECRUITING
Registry status
100 participants
Enrollment target
10
Study locations

Study Summary

A multi-centre, multi-country, observational, non-interventional, retrospective and prospective (hybrid) study among Fabry disease participants treated with pegunigalsidase alfa (Elfabrio®) in routine clinical care.

Conditions Studied

Fabry Disease

Interventions

  • DRUG Pegunigalsidase-alfa

Study Locations (10)

Other

  • General Hospital Slovenj Gradec - Slovenj Gradec
  • The Royal Free Hospital - London

Alabama

  • University of Alabama at Birmingham - Birmingham

Georgia

  • Emory University School of Medicine - Atlanta

Illinois

  • Northwestern University - Feinberg School of Medicine - Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago

Iowa

  • University of Iowa Hospitals and Clinics - Iowa City

Michigan

  • Infusion Associates - Grand Rapids

Virginia

  • Lysosomal & Rare Disorder Research & Treatment Center (LRDRTC) - Fairfax

Birmingham

  • University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital - Edgbaston

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2024-11-06
Est. Completion 2029-11

Sponsor

Chiesi Farmaceutici S.p.A.

30 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06663358

The ClinicalTrials.gov registry entry for NCT06663358 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 540-participant average among 32 other Fabry Disease trials with a reported enrollment target (81% lower). The listed sponsor is Chiesi Farmaceutici S.p.A., which has 30 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Fabry Disease appearing as the primary indexed condition, and to 1 intervention - of which Pegunigalsidase-alfa is the first listed.

NCT06663358 reports 10 study locations spanning 9 distinct geographic areas - top geographies include Other, Alabama, Georgia.

Frequently Asked Questions

What is clinical trial NCT06663358 about?

NCT06663358 is a clinical study titled "A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients". A multi-centre, multi-country, observational, non-interventional, retrospective and prospective (hybrid) study among Fabry disease participants treated with pegunigalsidase alfa (Elfabrio®) in routine clinical care.

What is the current status of trial NCT06663358?

This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2024-11-06. Estimated completion is 2029-11.

What conditions does trial NCT06663358 study?

This clinical trial studies the following conditions: Fabry Disease.

What interventions are being tested in trial NCT06663358?

The interventions under investigation include: Pegunigalsidase-alfa (DRUG).

Who is sponsoring clinical trial NCT06663358?

This trial is sponsored by Chiesi Farmaceutici S.p.A., which has 30 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06663358 being conducted?

This trial has 10 study locations across Alabama, Georgia, Illinois, Iowa, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Fabry Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Fabry Disease

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.